At present, China's innovative drug research and development is showing a vigorous growth trend, and the gap between China's new drug R&D and the world is gradually narrowing, but with more players entering the market,competition is becoming more intense. Currently, the domestic market is no longer well capitalized, targets are full, and more competition under pressure to enter health insurance. At the same time, the continuous progress of drug development and changing regulatory approval requirements in the international market have put forward higher requirements for domestic pharmaceutical companies' innovative drug development capabilities, clinical trial design capabilities, domestic and international clinical trial promotion capabilities, and communication capabilities with regulatory authorities. In the current situation of intensified competition, returning to the origin of innovation and promoting differentiated innovation oriented to clinical value has become the main theme of China's pharmaceutical industry development.
Based on this, The 12th Asia Pharma R&D Leaders 2023, themed "Patient-Centered, Innovation-Enabled Clinical", will be held again in Shanghai on August 24-25, 2023, and will again bring together 90+ pharmaceutical R&D leaders and 1000+ industry colleagues on the basis of the success of the previous 11 conferences, deeply explore differentiated R&D strategies, strive to improve clinical development efficiency, promote the internationalization of innovative drug R&D, patient-centered,and return to the origin of innovation, and to make innovation truly empowering to the clinic!